Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cureus|July 13, 2022
Histiocytic Sarcoma: Clinical Features and Outcomes of Patients Treated at a Tertiary Cancer Care CenterDeepa Susan Joy Philip, Amitha Sherief, Geetha Narayanan, et al.
Cureus|March 6, 2023
Lymphoma and Differentiated Thyroid Cancer: A Case SeriesAmitha Sherief, Sugeeth M Thambi, Deepa Susan Joy Philip, et al.
Oncotargets and Therapy|June 28, 2017
Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatmentVanita Noronha, Anuradha Choughule, Vijay M Patil, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|February 23, 2026
Expression of Programmed Death Ligand 1 (PD-L1) in Classical Hodgkin Lymphoma- Study from a Tertiary Care Cancer Centre in South IndiaP K Pravanya, Priya Mary Jacob, Rekha A Nair, et al.
Medicine International|November 6, 2023
Castleman disease: Experience from a single institutionSherry S Abraham, Geetha Narayanan, Sugeeth Mangalapilly Thambi, et al.
Journal of Cancer Research and Therapeutics|July 28, 2022
Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 - A comprehensive cytogenetic profiling of three cases with review of literatureT V Akhila Raj, Preethi Gopinath, J A Geetha Raj, et al.
Ecancermedicalscience|December 3, 2025
Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancerRohini Sebastian, Josh Thomas Georgy, Arun George, et al.
Scientific Reports|October 8, 2025
Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapyJosh Thomas Georgy, Soumya Susan Regi, Rosh Varghese Georgy, et al.
JCO Global Oncology|March 24, 2025
Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched AnalysisPraveen Kumar Marimuthu, Josh Thomas Georgy, Deepa Susan Joy Philip, et al.
The Lancet Regional Health. Southeast Asia|March 11, 2026
Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trialPraveen Kumar Marimuthu, Chitra Renukaradhya, Shalini Sahu, et al.
Pageof 1